The size of the Asia Pacific Animal Parasiticides Market was worth USD 2.58 billion in 2022. It is expected to be growing at a CAGR of 5.9% and worth USD 3.44 billion by 2027.
The market shows evident growth potential in the mentioned forecasting period. It is expected to expand in the future years with the gradual increase in awareness about animal health.
Animal parasiticides are the medications intended for the removal of all the parasites other than fungi and bacteria present on animals. They are generally non-reactive chemical substances which are mixed with each other and may have many different ingredients. Ingredients in a parasiticide generally have uniform chemical structures and have some common features. Often, they are categorized according to the chemical families they belong to. The animal parasiticides have high importance when it comes to protecting animals from parasitic diseases.
Rising pet population, Increasing the ability of people to spend on the healthcare of animals, growing concern for the quality of meat and animal products like leather and milk and the development in the R & D sector of animal healthcare have led to the growth of Asia-Pacific Animal Parasiticides market. However, growing inclination towards vegetarian and vegan lifestyles as well as strict restrictions on the approval for animal parasiticides are hindering the growth of the Asia-Pacific animal parasiticides market.
This research report on the Asia Pacific Animal Parasiticides Market has been segmented and sub-segmented into the following categories:
By Animal type:
Noteworthy companies dominating the Asia Pacific animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com